Human microphysiological systems for drug development

Roth, Adrian; Berlin, Mps-Ws

doi:10.1126/science.abc3734

Cited by 55 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the industry focuses on relevance, simplicity, reproducibility, and scalability at a competitive cost, academic research groups are the main drivers towards more complex and more diverse physiological and disease-relevant OoC platforms [ 18 , 19 , 20 ]. Increased complexity, however, comes along with reduced usability and the need for more hardware to operate the devices.…”

Section: Overview Of Organ-on-chip Technologymentioning

confidence: 99%

Academic User View: Organ-on-a-Chip Technology

et al. 2022

View full text Add to dashboard Cite

Organ-on-a-Chip (OoC) systems bring together cell biology, engineering, and material science for creating systems that recapitulate the in vivo microenvironment of tissues and organs. The versatility of OoC systems enables in vitro models for studying physiological processes, drug development, and testing in both academia and industry. This paper evaluates current platforms from the academic end-user perspective, elaborating on usability, complexity, and robustness. We surveyed 187 peers in 35 countries and grouped the responses according to preliminary knowledge and the source of the OoC systems that are used. The survey clearly shows that current commercial OoC platforms provide a substantial level of robustness and usability—which is also indicated by an increasing adaptation of the pharmaceutical industry—but a lack of complexity can challenge their use as a predictive platform. Self-made systems, on the other hand, are less robust and standardized but provide the opportunity to develop customized and more complex models, which are often needed for human disease modeling. This perspective serves as a guide for researchers in the OoC field and encourages the development of next-generation OoCs.

show abstract

Section: Overview Of Organ-on-chip Technologymentioning

confidence: 99%

Academic User View: Organ-on-a-Chip Technology

et al. 2022

View full text Add to dashboard Cite

show abstract

“…While the industry focuses on relevance, simplicity, reproducibility, and scalability at a competitive cost, academic research groups are the main drivers towards more complex and more diverse physiological and disease-relevant OoC platforms [19][20][21]. Increased complexity, however, comes along with reduced usability and the need for more hardware to operate the devices.…”

Section: Table 1 Overview Of Ooc Companiesmentioning

confidence: 99%

“…Fig. S1), we collected 165 answers from academia (144) and industry (21) in over 30 countries (Dataset in Suppl. Table S1).…”

Section: User-view Surveymentioning

confidence: 99%

User-View on Organ-on-a-Chip Technology

Busek¹,

Aizenshtadt²,

Martinez³

et al. 2022

Preprint

View full text Add to dashboard Cite

Organ-on-a-Chip (OoC) systems bring together cell biology, engineering, and material science for creating systems that recapitulate the in vivo microenvironment of tissues and organs. The versatility of OoC systems enables in vitro models for studying physiological processes, drug development, and testing in both academia and industry. This paper evaluates current platforms from the end-user perspective, elaborating on usability, complexity, and robustness. We surveyed 165 peers in over 30 countries and grouped the responses according to preliminary knowledge and the source of the OoC systems that are used. The survey clearly shows that current commercial OoC platforms provide a substantial level of robustness and usability - which is also indicated by an increasing adaptation of the pharmaceutical industry but a lack of complexity can challenge their use as a predictive platform. Self-made systems on the other hand are less robust and standardized but provide the opportunity to develop customized and more complex models which are often needed for human disease modeling. This review serves as a guide for researchers in the OoC field and encourages the development of next-generation OoCs.

show abstract

“…While MPS systems have been used for preclinical safety testing and internal decision making within the pharmaceutical industry, MPS assays have not been used in regulatory documentation for drug approval. In order for MPSs to take the next step from an investigative research device to a validated drug development tool, it will be imperative to have adequate validation and understanding of the systems to ensure they satisfy regulatory review requirements [73].…”

Section: Synergistic Partnerships Between Industry and Regulatory Bodies Are Driving Broad Adoption Of Oocs And Mpssmentioning

confidence: 99%

Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions

2021

View full text Add to dashboard Cite

For centuries, animal experiments have contributed much to our understanding of mechanisms of human disease, but their value in predicting the effectiveness of drug treatments in the clinic has remained controversial. Animal models, including genetically modified ones and experimentally induced pathologies, often do not accurately reflect disease in humans, and therefore do not predict with sufficient certainty what will happen in humans. Organ-on-chip (OOC) technology and bioengineered tissues have emerged as promising alternatives to traditional animal testing for a wide range of applications in biological defence, drug discovery and development, and precision medicine, offering a potential alternative. Recent technological breakthroughs in stem cell and organoid biology, OOC technology, and 3D bioprinting have all contributed to a tremendous progress in our ability to design, assemble and manufacture living organ biomimetic systems that more accurately reflect the structural and functional characteristics of human tissue in vitro, and enable improved predictions of human responses to drugs and environmental stimuli. Here, we provide a historical perspective on the evolution of the field of bioengineering, focusing on the most salient milestones that enabled control of internal and external cell microenvironment. We introduce the concepts of OOCs and Microphysiological systems (MPSs), review various chip designs and microfabrication methods used to construct OOCs, focusing on blood-brain barrier as an example, and discuss existing challenges and limitations. Finally, we provide an overview on emerging strategies for 3D bioprinting of MPSs and comment on the potential role of these devices in precision medicine.

show abstract

Human microphysiological systems for drug development

Abstract: icrophysiological systems (MPS ), such as microfluidic organs-onchips, have rapidly evolved as promising in vitro tools to recapitulate human physiology by recreating key biological processes and disease states. However, their value for drug development is only now becoming

Cited by 55 publications

References 15 publications

Academic User View: Organ-on-a-Chip Technology

Academic User View: Organ-on-a-Chip Technology

User-View on Organ-on-a-Chip Technology

Modelling Human Physiology on-Chip: Historical Perspectives and Future Directions

Contact Info

Product

Resources

About